Deeptech startup eNLife Analysis has raised Rs 6 crore in a seed funding spherical led by Piper Serica VC Fund to develop its blood-based biomarker platform for early detection of Alzheimer’s illness and different neurodegenerative issues.

The Bengaluru-based startup stated the funding will likely be used to construct and validate its biomarker platform, develop its analysis and improvement workforce, and advance its first diagnostic assay from prototype to clinical-grade validation.

Based in 2025 by Deepak Kumaran Nair, Jojo Jacob and Anish Mathew, eNLife is creating an AI-powered blood take a look at that goals to detect Alzheimer’s illness years earlier than medical signs seem.

The startup’s platform analyses biomarkers linked to neurodegenerative ailments and makes use of AI to establish early indicators of illness development. In response to eNLife, the take a look at is designed to be administered by means of routine diagnostic centres and ship outcomes inside two to 5 hours.

Typical diagnostic strategies resembling PET scans, MRI scans and cerebrospinal fluid evaluation may be costly or invasive, and are sometimes used later within the prognosis course of. eNLife stated its method is geared toward making early detection extra accessible and reasonably priced.

“The most important failure of Alzheimer’s care as we speak isn’t the absence of therapies in trials; it’s that we discover sufferers a decade too late to make use of them,” stated Deepak Kumaran Nair, co-founder and CEO of eNLife Analysis.

“We began eNLife to shut each gaps directly: detect the illness on the molecular stage by means of a easy blood draw that’s each accessible and reasonably priced,” he stated.

Additionally it is creating next-generation assays able to monitoring as much as 100 organic markers for a number of types of dementia and different neurodegenerative issues.

eNLife is collaborating with researchers related to the Indian Institute of Science, the Nationwide Institute of Psychological Well being and Neurosciences, the Tata Institute of Elementary Analysis Hyderabad, and the Centre for Mind Analysis in Bengaluru to construct India-specific biomarker datasets.

The platform is being designed round Indian genetic and life-style danger profiles. It expects to start submitting patents over the subsequent 9 to 18 months throughout biomarker binders, diagnostic assays and its detection platform.

“India may have one of many world’s largest ageing populations inside a technology, and neurodegenerative illness is the burden we’re least ready for,” stated Rajni Agarwal, director at Piper Serica.

“Piper Serica VC Fund backs technologically differentiated class creators, and eNLife is the primary we’ve seen that modifications the standard of life fairly than merely extending it,” she stated.